Endowus have selected the Fund for its proven track record, stable investment team, and competitive pricing.
Fund Objective: Aims to achieve a combination of growth and income by investing in companies listed on Chinese stock exchanges, and aims to outperform the MSCI China A Index benchmark (before charges).
Suitability: Investors who wish to seek capital appreciation opportunities through equity investments, use this Fund as a complement to a diversified portfolio or a stand-alone core equity portfolio, and have long-term investment horizon.
* Total Fund-level Fees include fund management fee of 1.75%.
** Endowus do not charge an upfront sales charge or any other fees, other than the all-in Access Fee.
Fund Inception: 16 March 2015
Share Class Inception: 22 July 2018
Benchmark: MSCI China A Index
Fund AUM: SGD 6.6bn
Source: MorningStar as of 8 March 2021. Please refer to the FMC page for the most updated AUM.
Source: MorningStar as of 31 January 2020. Allocation data indicate actual exposure as a percentage of the Fund's total Net Asset Value. Please refer to the Fund Manager Page for the most updated information on Fund Holdings and Breakdown.
Endowus have selected Aberdeen Standard SICAV I - China A Share Equity Fund for its proven track record, stable investment team, and competitive pricing. The Fund has the longest track record amongst its available peers for retail investors in Singapore. It has also realised significant outperformance against the benchmark, MSCI China A Index, since its inception in 2015, and has consistently been in the top 25 percentile of performers against its global peers. The Fund takes a long-term investment horizon with an emphasis on quality, therefore realising maximum drawdown levels that are better than its global peer’s average.
The Fund has had a stable portfolio management team since inception, with Nicholas Yeo being lead manager, supported by 12 China analysts covering about more than 100 names. After the Endowus trailer fee rebates, the 1.14% fund-level fees are very competitively priced against its peers.
Updated by Endowus: June 2021
**Disclaimer: All content found on this page is for information purposes only and should not be considered as an offer, solicitation or advice for the purchase or sale of any investment products. It is recommended that you seek financial advice as to the suitability of any investment. Whilst Endow.us Pte. Ltd. (“Endowus”) has tried to provide accurate and timely information, there may be inadvertent delays, omissions, technical or factual inaccuracies or typographical errors. Any opinion or estimate above is made on a general basis and none of Endowus, nor any of its affiliates, representatives or agents have given any consideration to nor have made any investigation of the objective, financial situation or particular need of any user, reader, any specific person or group of persons. Opinions expressed herein are subject to change without notice.
Investment involves risk. The value of investments and the income from them can go down as well as up, and you may not get the full amount you invested. Past performance is not an indicator nor a guarantee of future performance. Rates of exchange may cause the value of investments to go up or down. Individual stock performance does not represent the return of a fund.
Please note that the above information does not purport to be all-inclusive or to contain all the information that you may need in order to make an informed decision. The information contained herein is not intended, and should not be construed, as legal, tax, regulatory, accounting or financial advice.